ArticleJournal of nanobiotechnology2025
RGD-HSA-TAC nanoparticles targeted delivery of tacrolimus and attenuation of podocyte injury in diabetic kidney disease.
Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Nanotechnology-mediated podocyte injury repair: mechanistic exploration and therapeutic prospects.Renal failure · 2026Review
- WTAP Deficiency Promotes Podocyte PANoptosis and FSGS via SPP1 Signaling.Circulation research · 2026Article
- Design of Nanocarriers for Kidney Targeted Delivery of Nucleic Acid Therapeutics.Macromolecular bioscience · 2026Review
- The dysregulated unfolded protein response in diabetic kidney disease: mechanisms and crosstalk with cell death pathways.Frontiers in pharmacology · 2026Review
- Translational advances in diabetic nephropathy management: integrating nanoformulation-based drug delivery systems.Frontiers in medical technology · 2026Review
- Immune-mediated renal injury in diabetic kidney disease: from mechanisms to therapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundDiabetic kidney disease (DKD) is a prevalent and severe complication of diabetes and plays a pivotal role in the pathogenesis and progression of DKD. However, the current clinical application of the treatment methods does not yield effective results. Tacrolimus has been utilized in the management of immune-mediated and genetic-mediated nephropathy, with an emphasis on the restoration of podocyte cytoskeletal integrity and inhibition of apoptosis. The clinical management of diabetic nephropathy with tacrolimus remains challenging because of the risk of worsening hyperglycemia and infection.
resultsWe developed two RGD-HSA-TAC nanoparticles designed for targeted delivery of tacrolimus to podocytes. Administration of SANPs and CNPs resulted in elevated levels of tacrolimus in podocytes, leading to a reduction in podocyte damage and albuminuria in diabetic nephropathy mice. Furthermore, the use of SANPs and CNPs resulted in a decrease in tacrolimus accumulation in the pancreas, lymph nodes, and thymus, thereby reducing the potential to exacerbate hyperglycemia and infection. Importantly, compared to tacrolimus alone, both SANPs and CNPs demonstrated superior therapeutic efficacy, with CNPs exhibiting a greater advantage over SANPs.
conclusionsCompared to tacrolimus, SANPs and CNPs demonstrated superior therapeutic efficacy and a reduced incidence of adverse effects in the treatment of diabetic nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.